AI and Medical Technology company Echo IQ announced that its cloud-based enhanced screening platform for structural heart disease, commencing with aortic stenosis, is now available to registered customers in the US. The platform will be sold under the name EchoSolv which has been chosen to reflect the importance of identifying patients at risk of structural heart disease, and the vital role that analysis of echocardiograms plays in meeting that challenge. The EchoSolv software platform is designed to support clinicians and physicians in identifying patients with guideline-defined aortic stenosis in the first instance.

Whilst treatment options for sufferers of severe aortic stenosis are considered safe and reliable, the condition has a 2 -year mortality rate of 50% when left untreated. EchoSolv TM is designed to ensure patients who would benefit from treatment or further clinical review are accurately identified. The rigorously tested product has been developed in consultation with leading cardiologists.

Echo IQ's Chief Medical Advisor and Cardiologist, Professor David Playford indicates that EchoSolv "automates the identification of high-risk aortic stenosis patients. It heralds the beginning of a new era by improving the cardiologist's focus on patients at-risk without requiring any change of cardiac imaging solution, no new hardware, no new devices, and no new interference with existing infrastructure." Key Product Features: Rapid automated assessment of echocardiographic measurements for consistent analysis. Bulk assessments completed at a rate of up to 48,000 per minute.

EchoSolv dashboard displays whether in-guideline thresholds have been met plus displays of key measurements and time-stamped assessments. Optional SMS/Email alerts for high-risk patients. Results can be exported in PDF and other formats.

Ability to deploy platform to new markets incorporating local regulatory frameworks. Available Web Application Programming Interface (API) supports optional integration into existing workflows/systems for real-time results. Role based access controls for audit and usage traceability.

Cloud-based HIPAA and SOC2 compliant platform ensures security of patient and provider information. Echo IQ is initially introducing EchoSolv in the United States where the Company has recently achieved positive results with the product in a clinical efficacy study with Harvard Medical School's Beth Israel Deaconess Medical Center. This study demonstrated that EchoSolv successfully identified sizeable cohorts of patients with guideline-detected severe aortic stenosis as well those with a significantly heightened risk of death from the condition.